In AD, TREM2 inhibits complement-mediated synaptic elimination during neurodegeneration to protect cognitive function [9–14, 40, 41], and acts downstream of CD33, alleviating pathological deposition of amyloid β (Aβ) and improving cognitive function in 5xFAD mice [16]. The gene discussed is CD33; the disease is Alzheimer disease.